# Glenview Capital Management

> Glenview Capital Management is a VC fund backing Health Care and Medical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 11
- Last investment: Nov 2024
- Lead investor: 36%
- Last updated: Aug 2026

Glenview Capital Management is a hedge fund founded in 2000 with approximately $9.2 billion of capital under management.

## Contacts

5 contacts available for Glenview Capital Management. Shizune tracks 3 team members at Glenview Capital Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/glenview-capital-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 55% |
| Medical | 3 | 27% |
| Medical Device | 3 | 27% |
| Manufacturing | 2 | 18% |
| Semiconductor | 2 | 18% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 3 | 27% |
| Series D | 2 | 18% |
| Series A | 1 | 9% |
| Series B | 1 | 9% |
| Series C | 1 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 64% |
| United Kingdom | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dennis Chao | Senior Analyst - Therapeutics | 0 | — |
| Larry Robbins | Founder and CEO | 1 | — |
| Lee Hathaway | Partner, Co-Head of Healthcare at Glenview Capital | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $60M | Series E | Nov 18, 2024 |  |
| Detect | Detect they build tools that empower people to understand their health. |  | Series C | Nov 15, 2022 |  |
| Limber | Limber Health is enabling the delivery of the world’s leading hybrid model of in-person and digital musculoskeletal (MSK) care. Developed by physical therapists and physicians, Limber Health empowers providers with a complete digital toolkit for Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), Outcomes Collection, MIPS Reporting,and the shift to value-based care. Clinically validated through research conducted at Mayo Clinic and awarded Most Impactful New Technology by the American Congress of Rehabilitation Medicine, Limber empowers providers in augmenting in-person clinician visits with digital at-home support to best meet patients where they are. | $16M | Series A | Oct 20, 2022 |  |
| Limber | Limber Health is enabling the delivery of the world’s leading hybrid model of in-person and digital musculoskeletal (MSK) care. Developed by physical therapists and physicians, Limber Health empowers providers with a complete digital toolkit for Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), Outcomes Collection, MIPS Reporting,and the shift to value-based care. Clinically validated through research conducted at Mayo Clinic and awarded Most Impactful New Technology by the American Congress of Rehabilitation Medicine, Limber empowers providers in augmenting in-person clinician visits with digital at-home support to best meet patients where they are. | $16M | Series A | Oct 20, 2022 |  |
| Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $245M | Series D | Jun 23, 2021 |  |
| Quantum SI | Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what hasbeen possible with DNA sequencing. | $425M | Post-IPO Equity | Jun 11, 2021 |  |
| Tesseract Health | Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, andPalo Alto, California. | $80M | Series B | Apr 20, 2021 |  |
| Tesseract Health | Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, andPalo Alto, California. | $80M | Series B | Apr 20, 2021 |  |
| Butterfly Network | Butterfly has created the world's first handheld, single-probe whole-body ultrasound system using its patented Ultrasound-on-Chip™ semiconductor technology. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, including for the 4.7 billion people around the world lacking access toultrasound. Butterfly is paving the way for earlier detection and remote management of health conditions around the world. | $175M | Post-IPO Equity | Feb 16, 2021 |  |
| SunEdison | SunEdison is your trusted partner for innovative, intelligent energy solutions around the globe. We have built our business by putting our customers first, and focusing on addressing each customer's unique solar energy needs. Through our integrated service approach, we partner with you, help you navigate your way through the solar landscapeand offer uniquely tailored solutions and flexible financing. | $402.5M | Post-IPO Equity | Jun 16, 2015 |  |

10 of 11 investments shown.

## Co-investors
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 6 deals together
- [Eldridge Industries](https://shizune.co/investors/profile/eldridge) — VC Fund, 4 deals together
- [Eldridge Industries](https://shizune.co/investors/profile/eldridgeindustries) — VC Fund, 3 deals together
- Affinity Asset Advisors — VC Fund, 2 deals together
- [Blue Cross Blue Shield Association](https://shizune.co/investors/profile/blue-cross-and-blue-shield-association) — VC Fund, 2 deals together
- [The Blue Venture Fund](https://shizune.co/investors/profile/bluecross-blueshield-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Glenview Capital Management invest in?

Glenview Capital Management invests primarily in Health Care, Medical and Medical Device startups, most often at Post-IPO Equity and Series D stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Glenview Capital Management?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Glenview Capital Management?

The team at Glenview Capital Management includes Dennis Chao (Senior Analyst - Therapeutics), Larry Robbins (Founder and CEO) and Lee Hathaway (Partner, Co-Head of Healthcare at Glenview Capital). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co